Bioresorbable Scaffold Program Update. Alexandre Abizaid, MD, PhD, FACC Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil

Transcription

1 Bioresorbable Scaffold Program Update Alexandre Abizaid, MD, PhD, FACC Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil

2 Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below REVA Medical: research grants and advisory board

3 REVA s Technology Transition to the Fantom Scaffold 2011: ReZolve Slide & Lock Platform Non deformable design based upon slide & lock technology Currently being evaluated in 112 patients in the RESTORE II Study Preliminary results Acute technical success > 95% Follow up ongoing per clinical protocol 2014: REVA Transition to the Fantom Platform Designed to be deliverable, strong, visible, and easy to use tyrosine polycarbonate

4 Fantom Sirolimus Eluting Bioresorbable Scaffold Desaminotyrosine Derived Polycarbonate

5 BRS Desired Features Scaffold profile Radial force Visibility Post dilation without fracture Degradation time

6 Fantom Has a Low Crossing Profile Effect of Strut Thickness on Crossing Profile ASmall Change has a Big Impact PLLA Scaffold 1.4 mm (.055 ) Fantom <1.27 mm (.050 ) A reduction in strut thickness of only µm achieves >10% decrease in profile and significant improvements in deliverability

7 BRS Desired Features Scaffold profile Radial force Visibility Post dilation without fracture Degradation time

8 Polymer Foundation for the Fantom Scaffold REVA Polymer Family vs. Competitive Polylactide Based Polymers REVA Polymer Family High performance biomaterials Competitive Polymers Polylactide based Based on phenyl ring structure Based on Alkane structure Phenyl ring structure provides high strength, radiopaque materials without compromising structural properties

9 Fantom Designed with Thinner Struts Without Compromising Strength The design achieves low strut thickness without sacrificing scaffold strength Strut Thickness Decreased strut thickness impacts strength and crossing profile * Metal Drug Eluting Stent

10 Fantom Maintains Radial Strength With Reduced Strut Thickness Strength FANTOM PLLA STRUT THICKNESS (µ) Advanced polymer properties enable reduced strut thickness

11 Fantom Radial Strength Fantom strength is comparable with decrease in strut thickness In house comparison testing against Absorb 3.0 mm x 18 mm scaffold

12 BRS Desired Features Scaffold profile Radial force Visibility Post dilation without fracture Degradation time

13 Fantom is Completely Visible Under X Ray Fantom s complete (x ray) visibility increases confidence during the procedure Precise scaffold placement Complete lesion coverage No geographic miss Confirmation of apposition to vessel wall Reduces need for IVUS & OCT catheter use Cost savings to hospital No permanent metal markers left behind Absorb Fantom Xience Fantom

14 BRS Desired Features Scaffold profile Radial force Visibility Post dilation without fracture Degradation time

15 Fantom Enables Standard Implant Procedure Traditional Inflation and Expansion Range Single step inflation directly to intended diameter No need for intermediate steps Post dilation without compromise Substantial safety margin Large expansion range without the concern of fracture 3.0mm Nominal Device Capable of expansion to >4.8mm without fracture Able to adjust for vessel taper to meet vessel apposition needs

16 Fantom Bioresorbable Scaffold Single Step Inflation REVAs advanced polymer enables single step inflation

17 BRS Desired Features Scaffold profile Radial force Visibility Post dilation without fracture Degradation time

18 Fantom Offers Optimal Degradation & Resorption Degradation Greater than 80% degradation within one year Full restoration of natural vasomotion Eliminates undesirable shear stress induced by a permanent implant Resorption Complete resorption within ~3 years

19 Fantom Preclinical Results Confirm Performance Angiographic, IVUS and OCT Images thru 3 Months Visibility, conformability and maintenance of vessel patency

20 Fantom Clinical Plan First patient implants anticipated Q4 14 All CE sites fully enrolling by early 2015 Up to 125 patients Over 20 clinical investigational centers AUS, BE, BR, DK, FR, DE, NL and PL Primary endpoints MACE and late lumen loss at six months

21 Fantom Bioresorbable Scaffold Overview Visibility Strength Ease of Use Improved deliverability with reduced profile Superior scaffold visibility Expansion with one smooth and continuous inflation No requirement for stepped inflation Post dilation without compromise Scaffold strength to treat challenging lesions No procedural time limitations No special storage requirements